Blar i forfatter Artikler, rapporter og annet (medisinsk biologi) "Ueland, Thor"

Viser treff 1-3 av 3

    • Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9 

      Lerum, Tøri Vigeland; Maltzahn, Niklas; Aukrust, Pål; Trøseid, Marius; Nezvalova-Henriksen, Katerina; Kåsine, Trine; Dyrhol-Riise, Anne Ma; Stiksrud, Birgitte; Haugli, Mette; Blomberg, Bjørn; Kittang, Bård Reiakvam; Johannessen, Asgeir; Hannula, Raisa; Aballi, Saad; Kildal, Anders Benjamin; Eiken, Ragnhild; Dahl, Tuva Børresdatter; Lund-Johansen, Fridtjof; Müller, Fredrik; Rivero, Jezabel Rodriguez; Meltzer, Carin; Einvik, Gunnar; Ueland, Thor; Olsen, Inge Christoffer; Barratt-Due, Andreas; Aaløkken, Trond Mogens; Skjønsberg, Ole Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-12-01)
      The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DL<sub>CO</sub>), and chest-CT were performed at 23 Norwegian hospitals included in the NOR-SOLIDARITY trial, an open-labelled, ...

    • Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma 

      Nyakas, Marta Sølvi; Aamdal, Elin; Jacobsen, Kari Dolven; Guren, Tormod Kyrre; Aamdal, Steinar; Hagene, Kirsten Thorin; Brunsvig, Paal Fr.; Yndestad, Arne; Halvorsen, Bente; Tasken, Kristin Austlid; Aukrust, Pål; Mælandsmo, Gunhild Mari; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-03-01)
      New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients with metastatic or unresectable malignant melanoma, receiving treatment with ipilimumab in a national ...

    • Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers 

      Nome, Marianne Eikhom; Euceda, Leslie R.; Jabeen, Shakila; Debik, Julia; Bathen, Tone Frost; Giskeødegård, Guro F.; Tasken, Kristin Austlid; Mælandsmo, Gunhild Mari; Halvorsen, Bente; Yndestad, Arne; Borgen, Elin; Garred, Øystein; Aukrust, Pål; Ueland, Thor; Engebraaten, Olav; Kristensen, Vessela N.; Tekpli, Xavier (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-08-24)
      Angiogenesis is necessary for tumor growth and has been targeted in breast cancer; however, it is unclear which patients will respond and benefit from antiangiogenic therapy. We report noninvasive monitoring of patient response to neoadjuvant chemotherapy given alone or in combination with anti‐vascular endothelial growth factor (bevacizumab) in a randomized clinical trial. At four time points during ...